ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.
Company profile
Ticker
IONS
Exchange
Website
CEO
Brett Monia
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ISIS PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Akcea Therapeutics, Inc. • Akcea Therapeutics Canada Inc. • Akcea Therapeutics Germany GmbH • Akcea Therapeutics UK Limited • Akcea Therapeutics Ireland Limited • Akcea Therapeutics Italia S.r.l. • Akcea Therapeutics Portugal, Unipessoal Lda, a Portuguese Company • Ionis Faraday LLC • Ionis Gazelle LLC • Ionis Ireland Limited ...
IRS number
330336973
IONS stock data
Latest filings (excl ownership)
8-K
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
8 Apr 24
8-K
Entry into a Material Definitive Agreement
29 Feb 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
Ionis reports fourth quarter and full year 2023 financial results
21 Feb 24
8-K
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
22 Jan 24
8-K
Other Events
21 Dec 23
8-K
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
18 Dec 23
8-K
Ionis announces the appointment of Michael Yang to Board of Directors
14 Dec 23
S-3ASR
Automatic shelf registration
24 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
Transcripts
IONS
Earnings call transcript
2023 Q3
2 Nov 23
IONS
Earnings call transcript
2023 Q2
9 Aug 23
IONS
Earnings call transcript
2023 Q1
3 May 23
IONS
Earnings call transcript
2022 Q4
22 Feb 23
IONS
Earnings call transcript
2022 Q3
9 Nov 22
IONS
Earnings call transcript
2022 Q2
9 Aug 22
IONS
Earnings call transcript
2022 Q1
4 May 22
IONS
Earnings call transcript
2021 Q4
24 Feb 22
IONS
Earnings call transcript
2021 Q3
3 Nov 21
IONS
Earnings call transcript
2021 Q2
4 Aug 21
Latest ownership filings
4
Joseph Baroldi
17 Apr 24
4
Brian Birchler
17 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
4
Kyle Jenne
13 Mar 24
3
Kyle Jenne
13 Mar 24
4
Eric Swayze
4 Mar 24
4
Brett P Monia
4 Mar 24
4
Richard S Geary
4 Mar 24
4
Brian Birchler
4 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 352.06 mm | 352.06 mm | 352.06 mm | 352.06 mm | 352.06 mm | 352.06 mm |
Cash burn (monthly) | 24.24 mm | (no burn) | 47.76 mm | 46.30 mm | 36.34 mm | 45.05 mm |
Cash used (since last report) | 166.01 mm | n/a | 327.01 mm | 317.06 mm | 248.85 mm | 308.47 mm |
Cash remaining | 186.05 mm | n/a | 25.05 mm | 35.00 mm | 103.21 mm | 43.59 mm |
Runway (months of cash) | 7.7 | n/a | 0.5 | 0.8 | 2.8 | 1.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 311 |
Opened positions | 39 |
Closed positions | 30 |
Increased positions | 100 |
Reduced positions | 101 |
13F shares | Current |
---|---|
Total value | 6.28 tn |
Total shares | 153.76 mm |
Total puts | 229.10 k |
Total calls | 468.90 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
FMR | 21.50 mm | $975.19 bn |
Vanguard | 14.50 mm | $657.81 bn |
T. Rowe Price Investment Management | 13.12 mm | $595.58 bn |
BBBOF BB Biotech | 9.64 mm | $0.00 |
BLVGF Bellevue | 9.23 mm | $418.84 bn |
BLK Blackrock | 9.11 mm | $413.44 bn |
BIIB Biogen | 5.75 mm | $347.39 mm |
Clearbridge Advisors | 4.84 mm | $219.57 bn |
BVF | 4.00 mm | $181.65 bn |
STT State Street | 3.96 mm | $179.40 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Apr 24 | Brian Birchler | Common Stock | Sell | Dispose S | No | No | 41.6555 | 905 | 37.70 k | 46,156 |
16 Apr 24 | Joseph Baroldi | Common Stock | Sell | Dispose S | No | No | 41.5978 | 4,006 | 166.64 k | 19,631 |
15 Apr 24 | Brian Birchler | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,875 | 0.00 | 47,061 |
15 Apr 24 | Brian Birchler | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,875 | 0.00 | 44,373 |
15 Apr 24 | Joseph Baroldi | Common Stock | Option exercise | Acquire M | No | No | 0 | 10,838 | 0.00 | 23,637 |
15 Apr 24 | Joseph Baroldi | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 10,838 | 0.00 | 53,135 |
29 Feb 24 | Eric Swayze | Common Stock | Other | Acquire J | No | No | 34.425 | 605 | 20.83 k | 34,929 |
29 Feb 24 | Brett P Monia | Common Stock | Other | Acquire J | No | No | 34.425 | 538 | 18.52 k | 174,289 |
29 Feb 24 | Richard S Geary | Common Stock | Other | Acquire J | No | No | 34.425 | 604 | 20.79 k | 87,938 |
News
Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform
10 Apr 24
The Latest Analyst Ratings For Ionis Pharmaceuticals
9 Apr 24
Oppenheimer Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $75
9 Apr 24
Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
9 Apr 24
Ionis Pharmaceuticals Announced Olezarsen 80 Mg Monthly Dose Met The Primary Endpoint Of Significantly Reducing Triglycerides In Patients With Genetically Validated Fcs At Six Months
7 Apr 24
Press releases
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
7 Apr 24
Ionis to hold olezarsen Phase 3 data webcast
28 Mar 24
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
25 Mar 24
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
13 Mar 24
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
6 Mar 24